Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

In the published article, there was an error in Table 2. The count of monoclonal antibodies used was interchanged during production between the different antibodies. The corrected Table 2 and its caption appear below.

Table 2.

Immune-related adverse events and immunosuppression.

Baseline characteristics	Patients, n = 22 (%)
irAE
Grade 1	3 (13.6)
Grade 2	5 (22.7)
None	14 (63.6)
Liver irAE
Grade 1	2 (9.1)
Grade 2	1 (4.5)
Non–Liver irAE
Colitis	1 (4.5)
Pneumonitis	1 (4.5)
Inflammatory arthritis	1 (4.5)
Rash	2 (9.1)
Treatment regimen before ICI#
Mycophenolate mofetil	1 (4.5)
Azathioprine	4 (18.1)
Corticosteroids	2 (9.1)
Methotrexate*	1 (4.5)
UDCA	9 (40.9)
Obeticholic acid	1 (4.5)
No treatment for AILD	7 (31.8)
Treatment adjustment during ICI therapy due to non-liver related events#
Start Hydroxycholoroquine*	1 (4.5)
Start or increase of corticosteroids	2 (9.1)
No change in treatment	16 (72.7)
Treatment adjustment during ICI therapy due to ILICI or AILD#
Start or increase of corticosteroids	2 (9.1)
Start UDCA	1 (4.5)
Change from obeticholic acid to Fenofibrate	1 (4.5)
Stop Azathioprine	1 (4.5)
No change in treatment	16 (72.7)
Monoclonal antibody used
Atezolizumab	7 (31.8)
Durvalumab	5 (22.7)
Pembrolizumab	4 (18.1)
Nivolumab	4 (18.1)
Nivolumab + Ipilimumab	1 (4.5)
Spartalizumab	1 (4.5)

No changes in immunosuppressive therapy were made before commencing ICI treatment to prevent potential irAEs. #Multiple treatments possible *Treatment for Rheumatoid arthritis.

The authors apologize for this error introduced during production and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.